论文部分内容阅读
目的：将胃癌单克隆抗体（ ＭｃＡｂ） 组合提高ＭｃＡｂ 与人胃癌细胞系的反应性，为肿瘤定位诊断及导向治疗提供有效的ＭｃＡｂ 组合。方法：采用ＥＬＩＳＡ、ＦＣＭ 观察了单一胃癌ＭｃＡｂ 及组合ＭｃＡｂ 与人胃癌细胞系的反应性。结果：经ＥＬＩＳＡ、ＦＣＭ 分析单一的ＭｃＡｂ３Ｇ９ 、ＢＢ４．３ 与胃癌细胞结合的膜荧光阳性率分别为７４－２ ％ 和５４－９ ％ 。平均膜荧光强度分别为５３－６ 和６５－８。两者组合后，在相同抗体浓度下，膜荧光阳性率为９７－４ ％ （ Ｐ＜０－０１）；平均膜荧光强度为１２５－５（ Ｐ＜ ０－０１） 。结论：合理采用组合的ＭｃＡｂ 可提高ＭｃＡｂ 与人胃癌细胞系的反应性，降低抗原表达的异质性，从而提高ＭｃＡｂ 的载体效应。
OBJECTIVE: To improve the reactivity of McAb with human gastric cancer cell lines by combining McAb with gastric cancer, and to provide an effective McAb combination for tumor localization diagnosis and targeted therapy. Methods: The reactivity of single gastric cancer McAb and combination McAb with human gastric cancer cell line was observed by ELISA and FCM. RESULTS: The positive rates of the membrane-bound McAb3G9 and BB4.3 combined with gastric cancer cells by ELISA and FCM analysis were 74-2% and 54-9%, respectively. The mean membrane fluorescence intensities were 53-6 and 65-8, respectively. After the combination of the two, at the same antibody concentration, the membrane fluorescence positive rate was 97-4 % (P<0-01); the average membrane fluorescence intensity was 125-5 (P<0-01). CONCLUSION: The rational use of combination McAb can increase the reactivity of McAb with human gastric cancer cell lines, reduce the heterogeneity of antigen expression, and increase the carrier effect of McAb.